Welcome to Shanghai Probechem Biochemicals Co Ltd !Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : Tepotinib
CAS No.: 1100598-32-0
Catalog No.: PC-20461Not For Human Use, Lab Use Only.
Tepotinib (EMD1214063, MSC2156119) is a potent, specific and ATP-competitive inhibitor of MET (HGFR) with IC50 of 23 nM for MET WT autophosphorylation and 2.2-42.6 nM for M1268T, Y1248H, H1112Y, L1213V, H1112L, V1110I, V1206L, and V1238I MET-mutated variants.
| Packing | Price | Stock | Quantity |
|---|---|---|---|
| 10 mg | $188 | In stock | |
| 25 mg | $288 | In stock | |
| 100 mg | $598 | In stock | |
| 200 mg | Get quote | ||
| 1 g | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Tepotinib (EMD1214063, MSC2156119) is a potent, specific and ATP-competitive inhibitor of c-MET (HGFR) with IC50 of 23 nM for MET WT autophosphorylation and 2.2-42.6 nM for M1268T, Y1248H, H1112Y, L1213V, H1112L, V1110I, V1206L, and V1238I MET-mutated variants.
EMD1214063 displays higher IC50 values for V1206L, L1213V, and Y1248H variants (224.0, 270.1, and >1,000 nM, respectively), reduces the receptor Tyr1234/1235 autophosphorylation in NIH3T3 cell lines.
EMD1214063 inhibits the activation state of the MET downstream signaling molecules AKT, ERK, and PLCγ with IC50 of <75 nM in NIH3T3 mouse fibroblast cells stably expressing distinct MET-activating point mutations.
EMD1214063 selectively attenuates MET-dependent cell-cycle progression of cell lines expressing drug-sensitive forms of the MET receptor, shows high sensitivity agianst variants V1238I, M1268T, and H1112L (30 nM).
EMD1214063 (50 mg/kg/d) represses tumor growth in MET-driven xenograft drug-sensitive tumors bearing the H1112L MET mutation but not the drug-resistant MET mutants L1213V.
| M.Wt | 492.58 | |
| Formula | C29H28N6O2 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
| Chemical Name/SMILES |
3-(1-(3-(5-((1-methylpiperidin-4-yl)methoxy)pyrimidin-2-yl)benzyl)-6-oxo-1,6-dihydropyridazin-3-yl)benzonitrile |
|
1. Medová M, et al. Mol Cancer Ther. 2013 Nov;12(11):2415-24.
2. Bill KL, et al. Lab Invest. 2015 Aug;95(8):951-61.
3. Bladt F, et al. Clin Cancer Res. 2013;19:2941–51.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
